| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/30/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/02/2023 |
4
| Daves Julie VanOrsdel (SVP Clinical Development Oper.) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 54,000 options to buy
@ $2.73, valued at
$147.4k
|
|
| 06/02/2023 |
4
| Cundari Dominic R (Chief Commercial Officer) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 27,000 options to buy
@ $2.73, valued at
$73.7k
|
|
| 06/02/2023 |
4
| Gruis Kirsten L (Chief Medical Officer) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 67,000 options to buy
@ $2.73, valued at
$182.9k
|
|
| 06/02/2023 |
4
| Kellen Scott (CFO and Secretary) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 67,000 options to buy
@ $2.73, valued at
$182.9k
|
|
| 06/02/2023 |
4
| Pauls Dietrich John (President and CEO) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 181,000 options to buy
@ $2.73, valued at
$494.1k
|
|
| 06/02/2023 |
4
| Semba Charles Pauling (Director) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 16,968 options to buy
@ $2.73, valued at
$46.3k
|
|
| 06/02/2023 |
4
| Pilnik Richard D. (Director) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 22,355 options to buy
@ $2.73, valued at
$61k
|
|
| 06/02/2023 |
4
| Parsons James T. (Director) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 16,968 options to buy
@ $2.73, valued at
$46.3k
|
|
| 05/30/2023 |
4
| Kuntz Richard (Director) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 32,320 options to buy
@ $2.81, valued at
$90.8k
|
|
| 05/30/2023 |
3
| Kuntz Richard (Director) has filed a Form 3 on DiaMedica Therapeutics Inc. |
| 05/18/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 04/04/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/10/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/06/2023 |
4
| Lewis Tanya (Director) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 26,443 options to buy
@ $1.77, valued at
$46.8k
|
|
| 03/06/2023 |
3
| Lewis Tanya (Director) has filed a Form 3 on DiaMedica Therapeutics Inc. |
| 03/06/2023 |
8-K
| Resignation/termination of a director |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/13/2023 |
SC 13G/A
| JACINTO RICHARD II reports a 9.5% stake in DiaMedica Therapeutics Inc. |
| 01/03/2023 |
4
| Giuffre Randall Michael (Director) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 35,130 shares
@ $1.53, valued at
$53.7k
|
|
| 01/03/2023 |
4
| Burroughs Amy L. (Director) has filed a Form 4 on DiaMedica Therapeutics Inc.|
Txns:
| Granted 17,156 shares
@ $1.53, valued at
$26.2k
|
|
|